Evaluation of p53 expression among Colorectal Cancer patients
Background and purpose: Colorectal cancer (CRC) is counted as a third most common cancer among men and the second most common among women. Besides that, among cancer-related mortality, the 3rd most common cause of death is due to the CRC worldwide. A tumor suppressor gene p53 has the main role in regulating cell apoptosis, cell cycle arrest, and cell proliferation. Thus, abnormality in p53 such as mutation or overexpression has a significant association with human cancer, in which alteration in this gene can be found in more than 50% of different cancer cases. Therefore, our aim in this study is to evaluate the expression level of p53 gene focusing on its mRNA expression among colorectal cancer patients in Erbil, Kurdistan Region-Iraq.
Material and method: Forty-four pairs colorectal cancer tissues along with their corresponding non-cancerous tissues that were grouped based on the CRC types and patients’ clinical features. The expression of the p53 gene of the samples were evaluated by RT-PCR technique.
Result: results showed that expression of the p53 gene in colorectal cancer samples was significantly increased (overexpressed) compared to the expression of normal samples (control) (n=44, p=0, 0001).
Conclusion: It might be possible to consider the overexpression of the p53 gene as a molecular marker for colorectal cancer diagnosis in both men and women. However, for better understanding and confirming our opening findings further analysis are required.
ARNOLD, M., SIERRA, M. S., LAVERSANNE, M., SOERJOMATARAM, I., JEMAL, A. & BRAY, F. 2016. Global patterns and trends in colorectal cancer incidence and mortality. Gut, gutjnl-2015-310912.
DI AGOSTINO, S., STRANO, S. & BLANDINO, G. 2013. Gender, mutant p53 and PML: a growing “affaire” in tumor suppression and oncogenesis. Cell Cycle, 12, 1824-1825.
EL-MAHDANI, N., VAILLANT, J., GUIGUET, M., PREVOT, S., BERTRAND, V., BERNARD, C., PARC, R., BEREZIAT, G. & HERMELIN, B. 1997. Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. British journal of cancer, 75, 528.
GOEL, A. & BOLAND, C. R. 2012. Epigenetics of colorectal cancer. Gastroenterology, 143, 1442-1460. e1.
HUANG, K., CHEN, L., ZHANG, J., WU, Z., LAN, L., WANG, L., LU, B. & LIU, Y. 2014. Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. Oncology letters, 8, 1441-1446.
INAMURA, K. 2018. Colorectal Cancers: An Update on Their Molecular Pathology. Cancers, 10, 26.
KHAILANY, R. A., AL-ATTAR, M. S. & HASAN, A. A. 2017. Association of P53 gene expression alteration among breast cancer patients in Erbil province. Cukurova Medical Journal, 42, 205-209.
LAO, V. V. & GRADY, W. M. 2011. Epigenetics and colorectal cancer. Nature Reviews Gastroenterology and Hepatology, 8, 686.
LÁSZLÓ, L. 2010. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magyar onkologia, 54, 383-394.
LEE, J. Y., KIM, H. J., YOON, N. A., LEE, W. H., MIN, Y. J., KO, B. K., LEE, B. J., LEE, A., CHA, H. J. & CHO, W. J. 2013. Tumor suppressor p53 plays a key role in induction of both tristetraprolin and let-7 in human cancer cells. Nucleic acids research, 41, 5614-5625.
LIU, Z.-C., YANG, Z.-X., ZHOU, J.-S., ZHANG, H.-T., HUANG, Q.-K., DANG, L.-L., LIU, G.-X. & TAO, K.-S. 2014. Curcumin regulates hepatoma cell proliferation and apoptosis through the Notch signaling pathway. International journal of clinical and experimental medicine, 7, 714.
MURATA, A., BABA, Y., WATANABE, M., SHIGAKI, H., MIYAKE, K., KARASHIMA, R., IMAMURA, Y., IDA, S., ISHIMOTO, T. & IWAGAMI, S. 2013. p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma. Medical Oncology, 30, 728.
NCBI. 2018. Homo sapiens p53 (p53) gene [Online]. Available: https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?ORGANISM=9606&INPUT_SEQUENCE=JF923572.1&LINK_LOC=nuccore [Accessed].
SMITH, D., JI, C. & GOH, H. 1996. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. British journal of cancer, 74, 216.
THEODOROPOULOS, G. E., KARAFOKA, E., PAPAILIOU, J. G., STAMOPOULOS, P., ZAMBIRINIS, C. P., BRAMIS, K., PANOUSSOPOULOS, S.-G., LEANDROS, E. & BRAMIS, J. 2009. P53 and EGFR expression in colorectal cancer: a reappraisal of ‘old’tissue markers in patients with long follow-up. Anticancer research, 29, 785-791.
VAN HOUTEN, V. M., TABOR, M. P., VAN DEN BREKEL, M. W., ALAIN KUMMER, J., DENKERS, F., DIJKSTRA, J., LEEMANS, R., VAN DER WAAL, I., SNOW, G. B. & BRAKENHOFF, R. H. 2002. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 198, 476-486.
YAMASHITA, H., NISHIO, M., TOYAMA, T., SUGIURA, H., ZHANG, Z., KOBAYASHI, S. & IWASE, H. 2003. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Research, 6, R24.
Copyright (c) 2019 Harmand Ali Hama, Abdulkarim Y. Karim
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
At Zanco Journal, we're dedicated to protecting your rights as an author, and ensuring that any and all legal information and copyright regulations are addressed. Whether an author is published with Zanco Journal or any other publisher, we hold ourselves and our colleagues to the highest standards of ethics, responsibility and legal obligation